These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 26960892)

  • 1. [PCSK9 inhibitor is convincing a large analysis].
    Schlimpert V
    MMW Fortschr Med; 2015 Dec; 157(21-22):90. PubMed ID: 26960892
    [No Abstract]   [Full Text] [Related]  

  • 2. [Effective LDL cholesterol reduction for high risk patients].
    Einecke D
    MMW Fortschr Med; 2016 Apr; 158(8):84. PubMed ID: 27116175
    [No Abstract]   [Full Text] [Related]  

  • 3. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
    Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
    Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antibodies in addition to statin therapy lowers LDL cholesterol].
    Bossenmayer S
    Dtsch Med Wochenschr; 2012 Sep; 137(36):1728. PubMed ID: 23281534
    [No Abstract]   [Full Text] [Related]  

  • 5. [PCSK9 inhibitors: new treatment to lower cholesterol].
    Gencer B; Rodondi N; Mach F
    Rev Med Suisse; 2016 Mar; 12(508):440-2, 444. PubMed ID: 27089600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of PCSK9: is this the way forward for managing residual risk?
    Chowdhury SR; Rees A
    Curr Opin Lipidol; 2012 Oct; 23(5):509-10. PubMed ID: 22964999
    [No Abstract]   [Full Text] [Related]  

  • 7. Winner by points?--LDL cholesterol as a target for therapeutic intervention.
    Tietge UJ
    Curr Opin Lipidol; 2013 Jun; 24(3):277-8. PubMed ID: 23652473
    [No Abstract]   [Full Text] [Related]  

  • 8. [First PCSK9 inhibitor].
    Westphal K
    MMW Fortschr Med; 2016 Jun; 158(12):74. PubMed ID: 27462666
    [No Abstract]   [Full Text] [Related]  

  • 9. [First PCSK9 inhibitor].
    Westphal K
    MMW Fortschr Med; 2016 Jun; 158(12):74. PubMed ID: 27324017
    [No Abstract]   [Full Text] [Related]  

  • 10. Normalization of low-density lipoprotein receptor expression in receptor defective homozygous familial hypercholesterolemia by inhibition of PCSK9 with alirocumab.
    Lambert G; Chatelais M; Petrides F; Passard M; Thedrez A; Rye KA; Schwahn U; Gusarova V; Blom DJ; Sasiela W; Marais AD
    J Am Coll Cardiol; 2014 Dec; 64(21):2299-300. PubMed ID: 25456764
    [No Abstract]   [Full Text] [Related]  

  • 11. [PCSK9 inhibitors: emerging treatment to lower cholesterol?].
    Gencer B; Rodondi N; Mach F
    Rev Med Suisse; 2014 Mar; 10(420):539-42, 544. PubMed ID: 24701672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PCSK9 inhibitors.
    Gencer B; Lambert G; Mach F
    Swiss Med Wkly; 2015; 145():w14094. PubMed ID: 25856746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy and clinical trials.
    Sodhi N; Krasuski RA
    Curr Opin Lipidol; 2013 Jun; 24(3):281-2. PubMed ID: 23652475
    [No Abstract]   [Full Text] [Related]  

  • 14. [2nd PCSK9 inhibitor for effective LDL decrease].
    Einecke D
    MMW Fortschr Med; 2016 Feb; 158(2):65. PubMed ID: 26961048
    [No Abstract]   [Full Text] [Related]  

  • 15. [PCSK9 inhibition--A new era in cholesterol treatment].
    Olsson A
    Lakartidningen; 2015 Feb; 112():. PubMed ID: 25689006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.
    Raal FJ; Stein EA; Dufour R; Turner T; Civeira F; Burgess L; Langslet G; Scott R; Olsson AG; Sullivan D; Hovingh GK; Cariou B; Gouni-Berthold I; Somaratne R; Bridges I; Scott R; Wasserman SM; Gaudet D;
    Lancet; 2015 Jan; 385(9965):331-40. PubMed ID: 25282519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia.
    Stein EA; Honarpour N; Wasserman SM; Xu F; Scott R; Raal FJ
    Circulation; 2013 Nov; 128(19):2113-20. PubMed ID: 24014831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Familial hypercholesterolaemia: PCSK9 inhibitors are coming.
    Santos RD; Watts GF
    Lancet; 2015 Jan; 385(9965):307-10. PubMed ID: 25282517
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial.
    Raal FJ; Honarpour N; Blom DJ; Hovingh GK; Xu F; Scott R; Wasserman SM; Stein EA;
    Lancet; 2015 Jan; 385(9965):341-50. PubMed ID: 25282520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels: Effectiveness and Value.
    Tice JA; Kazi DS; Pearson SD
    JAMA Intern Med; 2016 Jan; 176(1):107-8. PubMed ID: 26662572
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.